LOGIN  |  REGISTER
Chimerix

Latest Diagnostics & Research Stock News

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

February 22
Last Trade: 19.42 -2.85 -12.80

Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif. / Feb 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1 million for...Read more


Waters to Present at the TD Cowen 44th Annual Health Care Conference

February 22
Last Trade: 331.25 0.70 0.21

MILFORD, Mass., Feb. 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Monday, March 4th, 2024 at 11:10AM Eastern Time A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website...Read more


Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

February 22
Last Trade: 4.46 0.05 1.13

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2,...Read more


Twist Bioscience to Present at Upcoming Investor Conferences

February 22
Last Trade: 38.20 -0.42 -1.09

SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside...Read more


Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

February 22
Last Trade: 66.27 1.22 1.88

Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023 Net cash provided by operating...Read more


Motus GI Announces Exercise of Warrants for $2.7 Million Gross Proceeds

February 22
Last Trade: 0.82 0.03 3.86

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of...Read more


MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

February 21
Last Trade: 3.57 -0.03 -0.83

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended...Read more


IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

February 21
Last Trade: 247.26 -0.07 -0.03

RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at...Read more


ICON Reports Fourth Quarter and Full Year 2023 Results

February 21
Last Trade: 314.19 0.82 0.26

Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a...Read more


Exact Sciences Announces Fourth Quarter 2023 Results

February 21
Last Trade: 57.53 -1.96 -3.29

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million Total 2023 revenue of $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of...Read more


Motus GI Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

February 21
Last Trade: 0.82 0.03 3.86

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further...Read more


Charles River Laboratories and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

February 21
Last Trade: 247.71 0.81 0.33

WILMINGTON, Mass. & OKLAHOMA CITY / Feb 21, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform. This...Read more


Revvity to Present at Upcoming Investor Conferences

February 21
Last Trade: 104.44 0.07 0.07

WALTHAM, Mass. / Feb 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024...Read more


Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

February 21
Last Trade: 0.94 -0.02 -1.71

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership...Read more


Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery

February 21
Last Trade: 127.08 1.74 1.39

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care BIRMINGHAM, Ala. and SAN FRANCISCO, Feb. 21, 2024 /PRNewswire/ -- Pack Health, a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery technology...Read more


CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

February 21
Last Trade: 8.27 0.00 0.00

BRISBANE, Calif. / Feb 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular...Read more


DarioHealth acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

February 21
Last Trade: 2.03 0.005 0.25

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK, Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the...Read more


QuidelOrtho Announces Changes in Executive Leadership

February 21
Last Trade: 46.89 0.34 0.73

The Board of Directors has terminated President and Chief Executive Officer, Douglas Bryant and appointed, on an interim basis, Michael Iskra as Chief Executive Officer and Robert Bujarski as President SAN DIEGO / Feb 21, 2024 / Business Wire / The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational efficiency, drive...Read more


NeoGenomics Reports Fourth Quarter and Full Year 2023 Results

February 20
Last Trade: 16.79 0.34 2.07

Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million FORT MYERS, Fla. / Feb 20, 2024 / Business Wire / NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue increased...Read more


IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

February 20
Last Trade: 576.29 4.98 0.87

WESTBROOK, Maine / Feb 20, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the...Read more


Charles River Laboratories Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 20
Last Trade: 247.71 0.81 0.33

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. / Feb 20, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The...Read more


T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

February 15
Last Trade: 5.42 -0.06 -1.09

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023. Full Year 2023 and Recent Commercial Highlights Achieved full year 2023 total revenue of $7.2...Read more


PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results

February 15
Last Trade: 5.11 -0.02 -0.39

MENLO PARK, Calif., Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period. Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. Consumables revenue of $18.9 million compared with...Read more


T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

February 15
Last Trade: 5.42 -0.06 -1.09

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands, Belgium, and Vietnam, as well as the re-entry into Switzerland. Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument,...Read more


Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

February 15
Last Trade: 0.51 -0.03 -5.56

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial. Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim...Read more


IDEXX Laboratories Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

February 15
Last Trade: 576.29 4.98 0.87

Initial Vello Users Show an Average 19% Reduction in No-Show Rate, Enabling More Clinical Visits WESTBROOK, Maine, Feb. 15, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of Vello, a software solution that seamlessly connects veterinary practices and clients through modern, digital tools. As the only pet owner engagement solution purpose-built for IDEXX...Read more


Labcorp Announces 2023 Fourth Quarter and Full Year Results

February 15
Last Trade: 219.16 1.39 0.64

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66 Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million...Read more


Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

February 15
Last Trade: 22.72 -0.38 -1.65

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she...Read more


ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

February 14
Last Trade: 1.15 0.00 0.00

Global Intellectual Property Portfolio Expands to 74 Issued Patents ANN ARBOR, Mich. / Feb 14, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS...Read more


IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

February 14
Last Trade: 247.26 -0.07 -0.03

Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20 for the...Read more


Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

February 14
Last Trade: 247.71 0.81 0.33

Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion  Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46  Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67  Provides 2024 Guidance  WILMINGTON, Mass. / Feb 14, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results...Read more


NRC Health Announces Fourth Quarter and Calendar Year 2023 Results

February 13
Last Trade: 40.00 0.33 0.83

LINCOLN, Neb. / Feb 13, 2024 / Business Wire / National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2023. CEO Commentary Michael Hays, Chief Executive Officer, commented: “We’re pleased to start 2024 with momentum from another consecutive quarter of growth in new sales and operating margin. We have trimmed non-core service lines, and developed our capability across the patient,...Read more


QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results

February 13
Last Trade: 46.89 0.34 0.73

Strong momentum in Labs business, with solid non-respiratory business growth and market share gains in industry-leading respiratory point-of-care portfolio Fourth Quarter 2023 Results and Highlights Revenue was $743 million, as reported: Non-respiratory revenue increased by 9% as reported and in constant currency Respiratory revenue decreased by 49% as reported and in constant currency GAAP net cash provided by operating...Read more


Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

February 13
Last Trade: 0.15 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is...Read more


Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging

February 13
Last Trade: 66.27 1.22 1.88

Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging...Read more


Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery

February 13
Last Trade: 127.08 1.74 1.39

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent  SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of...Read more


Medpace Reports Fourth Quarter and Full Year 2023 Results

February 12
Last Trade: 401.67 7.98 2.03

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%. Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of...Read more


Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

February 12
Last Trade: 104.44 0.07 0.07

Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements Seamless integration with Spotfire® for powerful visual analytics enabling flexibility, easy customization and scalability Fosters cross-functional collaboration and improves overall efficiency in clinical research and development WALTHAM, Mass. / Feb 12, 2024 / Business Wire / Today,...Read more


T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

February 12
Last Trade: 5.42 -0.06 -1.09

LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to the expansive...Read more


Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System

February 12
Last Trade: 3.29 0.01 0.30

MALVERN, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced advancements to the TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting system for providers using NeuroStar TMS...Read more


Quest Diagnostics: First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com

February 12
Last Trade: 127.08 1.74 1.39

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations interested in workforce, community, and research population testing may also access the test SECAUCUS, N.J., Feb. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leader in diagnostic information services, today...Read more


Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

February 12
Last Trade: 4.46 0.05 1.13

AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024. “Endometriomas are...Read more


Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

February 8
Last Trade: 133.00 -2.55 -1.88

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per...Read more


Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 8
Last Trade: 116.26 -1.24 -1.06

SAN DIEGO / Feb 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis....Read more


Trinity Biotech to Present at Emerging Growth Conference

February 8
Last Trade: 2.40 1.95 435.95

DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Please see the presentation information...Read more


Applied DNA Sciences Announces First Quarter Fiscal Year 2024 Financial Results

February 8
Last Trade: 0.65 -0.0075 -1.14

Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Million1 of Linea IVT Revenue2 Annually  Conference Call/Webcast Scheduled for Today at 4:30 PM ET  STONY BROOK, NY / ACCESSWIRE / February 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader...Read more


23andMe Reports Third Quarter Fiscal 2024 Financial Results

February 7
Last Trade: 0.57 -0.04 -5.83

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of...Read more


BioNxt Solutions Reports Successful Results From ODF Cladribine Toxicity Study

February 7
Last Trade: 0.63 0.03 5.00

VANCOUVER, BC / ACCESSWIRE / February 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that the toxicity study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed and results received by the Company. The study was unanimously successful with positive results in all study participants...Read more


Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

February 7
Last Trade: 2.45 0.10 4.26

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi™ Imaging System. This collaboration is pivotal in the fight against cancer, emphasizing the...Read more


Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code

February 7
Last Trade: 2.40 1.95 435.95

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability. It is estimated that up to approximately...Read more


Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

February 7
Last Trade: 5.58 -0.37 -6.22

First quarter fiscal 2024 revenue up 10.3% to $135.5 million First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million Shift to a renewed focus on sales and marketing as near-term infrastructure projects near completion Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract...Read more


QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability

February 6
Last Trade: 43.82 0.28 0.64

Venlo, the Netherlands, Feb. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio. Total sales for Q4 2023 rose 2% (+1% CER) to $509 million from Q4 2022, a period...Read more


Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

February 6
Last Trade: 6.21 -0.13 -2.05

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems...Read more


Neuronetics: NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

February 6
Last Trade: 3.29 0.01 0.30

MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation (TMS), such as NeuroStar® Advanced Therapy. The...Read more


Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

February 6
Last Trade: 38.20 -0.42 -1.09

Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / Feb 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today...Read more


Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

February 6
Last Trade: 38.20 -0.42 -1.09

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications SOUTH SAN FRANCISCO, Calif. / Feb 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using...Read more


Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines

February 6
Last Trade: 4.46 0.05 1.13

Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines, signs a 5-year OvaSuitSM commercial distribution agreement AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the signing of a 5-year distribution...Read more


Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

February 6
Last Trade: 0.94 -0.02 -1.71

BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announces the opening of the ‘European Oncology Lab’ (EOL). The physician-led facility represents an expansion of the Company’s collaboration with Laboratory Dr. Buhlmann with a shared location in Saarland,...Read more


Waters Reports Fourth Quarter and Full-Year 2023 Financial Results

February 6
Last Trade: 331.25 0.70 0.21

Highlights Fourth Quarter 2023 Sales of $819 million declined 4.5% as reported and 8% in organic constant currency, in line with guidance Operational excellence drove gross margin expansion of 170 basis points and adjusted operating margin expansion of 120 basis points Non-GAAP EPS of $3.62 at the high end of guidance; GAAP EPS of $3.65 Full-Year 2023 Strong execution in tough market conditions delivered sales of $2,956...Read more


Neogen Announces James Walter as Vice President, Global Operations

February 6
Last Trade: 16.96 -0.25 -1.45

LANSING, Mich., Feb. 6, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced that the Company has appointed James Walter to the position of Vice President, Global Operations. In this role, Mr. Walter will lead and manage Neogen's global manufacturing and logistics functions. Mr. Walter comes to Neogen after having spent most of his career at Mallinckrodt Pharmaceuticals and its predecessors, most recently as Executive...Read more


Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

February 6
Last Trade: 1.80 0.38 26.75

SAN ANTONIO / Feb 06, 2024 / Business Wire / Pharmaceuticals, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer including CyPath® Lung, today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company’s Medical and Scientific Advisory Board to provide expert advice and counsel on bioAffinity Technology products...Read more


PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

February 5
Last Trade: 5.11 -0.02 -0.39

New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif., Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system. With these kits, PacBio takes another leap forward...Read more


NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China

February 5
Last Trade: 0.95 -0.02 -2.48

E-Commerce Storefront to Initially Support Sales of up to 40 Personal Health and Wellness Products; Final International Certifications and Approvals Required for Formal Launch Expected This Quarter COCONUT GROVE, Fla., Feb. 5, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on Alibaba Group...Read more


Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

February 5
Last Trade: 38.20 -0.42 -1.09

Early access of novel technology that enables preparation of thousands of samples at low cost through self-normalization, enhanced multiplexing, and streamlined workflow Innovative solution positioned to drive NGS adoption in AgBio Twist Flex Prep UHT Kit and additional NGS tools to be highlighted at AGBT General Meeting SOUTH SAN FRANCISCO, Calif. / Feb 05, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a...Read more


Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

February 5
Last Trade: 1.56 0.00 0.00

Addition of another amino acid recognizer combined with improvements in surface chemistry, reagents and software will offer Platinum users greater sequencing output and coverage per sample BRANFORD, Conn. / Feb 05, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of...Read more


Natera: New Study Validates Signatera™ in Endometrial Cancer

February 5
Last Trade: 70.46 -0.69 -0.97

Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer AUSTIN, Texas / Feb 05, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD) test,...Read more


Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

February 5
Last Trade: 253.84 1.11 0.44

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched...Read more


Spectral Medical Provides Early February Tigris Trial Update

February 5
Last Trade: 0.51 -0.03 -5.56

88 patients enrolled January being the highest enrollment month since the launch of Tigris TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a...Read more


IDEXX Laboratories Announces Fourth Quarter and Full Year Results

February 5
Last Trade: 576.29 4.98 0.87

Achieves fourth quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 10% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 11% year-over-year expansion of IDEXX's global premium instrument installed base Delivers fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis Provides initial...Read more


Applied DNA Sciences Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

February 2
Last Trade: 0.65 -0.0075 -1.14

STONY BROOK, NY / ACCESSWIRE / February 2, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has closed its previously announced registered direct offering of its common stock priced at-the-market under Nasdaq rules with certain existing institutional investors (collectively the "Holders") for the sale of an aggregate of 5,644,061 of its shares of common stock...Read more


VolitionRx to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

HENDERSON, Nev., Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test. The webinar takes place on Tuesday, February 13th at 10:30 AM U.S. Eastern Time and will include updates from Volition's Mr. Gael Forterre (Chief...Read more


Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results

February 2
Last Trade: 38.20 -0.42 -1.09

Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 40% to 41% SOUTH SAN FRANCISCO, Calif. / Feb 02, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality...Read more


Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

February 1
Last Trade: 22.72 -0.38 -1.65

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Precise Tumor...Read more


Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

February 1
Last Trade: 32.79 0.92 2.89

EDEN PRAIRIE, Minn. / Feb 01, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024. First Quarter Fiscal 2024 Financial Summary Total Revenue of $30.6 million, an increase of 23%...Read more


Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share

February 1
Last Trade: 127.08 1.74 1.39

Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2022 Fourth quarter base business revenues of $2.25 billion, up 4.7% from 2022 Fourth quarter COVID-19 testing revenues of $37 million, down 79.8% from 2022 Full year revenues of $9.25 billion, down 6.4% from 2022 Full year reported...Read more


Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023

February 1
Last Trade: 104.44 0.07 0.07

Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25 Initiates full year 2024 guidance WALTHAM, Mass. / Feb 01, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The...Read more


23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

January 31
Last Trade: 0.57 -0.04 -5.83

23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells ‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function Phase 1 clinical study in patients with solid tumors to commence in H1 2024 The target for ‘1473 was discovered through 23andMe’s proprietary...Read more


Trinity Biotech Announces Q3 2023 Financial Results & Business Update

January 31
Last Trade: 2.40 1.95 435.95

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023. Business Updates and Strategic Priorities In December 2023, the Company announced the promotion of John Gillard from CFO to CEO and the promotion of Des Fitzgerald to the role of Interim CFO. The new management team has now put in place a clear set of strategies and...Read more


Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

January 31
Last Trade: 2.40 1.95 435.95

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India. This Letter of Intent is related to the Company’s recently announced acquisition of the CGM assets of Waveform Technologies, Inc.  Trinity has entered...Read more


Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women

January 31
Last Trade: 219.16 1.39 0.64

B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S.1 BURLINGTON, N.C., Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch...Read more


Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies

January 31
Last Trade: 2.40 1.95 435.95

Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management Upfront payment of $12.5 million cash and 9 million ADSs Strengthened investment relationship with Perceptive Advisors with the entry into an increased senior secured term loan credit facility with lower interest rates and Perceptive Advisors taking an approximately 20%...Read more


Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

January 31
Last Trade: 564.71 4.22 0.75

WALTHAM, Mass. / Jan 31, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%. Fourth quarter GAAP diluted EPS was...Read more


Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 31
Last Trade: 0.65 -0.0075 -1.14

STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the "Holders") for the issuance and sale of an aggregate of 5,644,061 of its shares of common stock (or prefunded warrants in lieu thereof) at a purchase...Read more


Agilent Technologies Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology

January 30
Last Trade: 132.03 0.01 0.01

SANTA CLARA, Calif. / Jan 30, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030,1...Read more


Bionano Genomics’ Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

January 30
Last Trade: 1.14 -0.02 -1.72

Over 2,100 registrants with attendees from 92 countries Average daily attendance of 574 32 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hall Content covered wide a range of research applications for OGM including hematologic malignancies, cell and gene therapy, and constitutional genetic diseases On-demand presentations from...Read more


Motus GI Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation

January 30
Last Trade: 0.82 0.03 3.86

FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, “An intraprocedural bowel cleansing system for difficult-to-prepare patients—A multicenter...Read more


Spectral Medical Provides January Tigris Trial Update

January 30
Last Trade: 0.51 -0.03 -5.56

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic...Read more


New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

January 30
Last Trade: 70.46 -0.69 -0.97

Clinical management was altered in 100% of patients with a Signatera positive result AUSTIN, Texas / Jan 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to risk stratify and...Read more


Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

January 30
Last Trade: 0.02 0.00 0.00

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery...Read more


Danaher Reports Fourth Quarter and Full Year 2023 Results

January 30
Last Trade: 253.84 1.11 0.44

WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.09. Revenues...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB